<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68989">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133040</url>
  </required_header>
  <id_info>
    <org_study_id>M-2013-236-13</org_study_id>
    <nct_id>NCT02133040</nct_id>
  </id_info>
  <brief_title>Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue</brief_title>
  <official_title>Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators wish to evaluate the effect of thyroid hormones on brown adipose tissue in
      humans in an observational study on patients with thyrotoxicosis. In the investigators
      evaluation the investigators will use FDG-PET/CT, indirect calorimetry and fat biopsies in
      the acute phase of the disease and in the euthyroid phase after treatment.

      It is the investigators hypothesis that high levels of circulating T3 might affect amount
      and function of brown adipose tissue.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>FDG-PET/CT-scanning</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Brown adipose tissue FDG uptake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Indirect Calorimetry</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in basal energy expenditure</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in adrenergic receptor status and UCP1, PGC1alpha, PRDM16 and Dio2 levels in subcutaneous fat depots</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hyperthyroidism</condition>
  <arm_group>
    <arm_group_label>T3 &gt; 4 nmol/l</arm_group_label>
    <description>Acute hyperthyroidism with a T3 &gt; 4 nmol/l</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum and fat tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        10 patients with hyperthyroidism, reffered to our hospital from their primary caretakers
        will be investigated before and after 3 to 5 months in a proven euthyroid state.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women with hyperthyroidism (T3 &gt; 3 nmol/l)

          -  &gt; 50 years old

          -  women must be postmenopausal

        Exclusion Criteria:

          -  thyrotoxic crises

          -  severe concurrent sickness that will make it unsafe to postpone treatment, this
             includes severe kidney disease (creatinin over 160)- and heart disease (NYHA group 3
             and 4).

          -  diabetes

          -  former and current treatment with interleukin-2

          -  Patients who are already treated with β-blockers

          -  severe claustrophobia

          -  BMI &gt; 30 kg/m2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjørn Richelsen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Breining, MD</last_name>
    <phone>+45 78467163</phone>
    <email>peter.breining@ki.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bjørn Richelsen, Professor</last_name>
    <phone>+45 7846 7696</phone>
    <email>bjoern.richelsen@aarhus.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <state>Region Midtjylland</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Breining, MD</last_name>
      <phone>+45 78457163</phone>
      <email>peter.breining@ki.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Lene Plagborg, Secretary</last_name>
      <phone>+45 7846 7696</phone>
      <email>leneplag@rm.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Breining</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Brown Adipose Tissue</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
